SUPN: Strong CNS portfolio growth, supply challenges for Onapgo, and active business development focus
Meno di 1 minuto di lettura
Revenue guidance is $685–$705 million, driven by four CNS products, with Qelbree and Onapgo showing strong growth. Onapgo faces supply constraints, while Zurzuvae is expanding in postpartum depression. Business development and pipeline expansion remain key priorities.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr